Adult Attention Deficit Hyperactivity Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

December 31, 2013

Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
DRUG

SEP-225289

SEP-225289 4mg once daily

DRUG

SEP-225289

SEP-225289 8mg once daily

DRUG

Placebo

Placebo once daily

Trial Locations (31)

11214

Brooklyn Medical Institutes, LLC, Brooklyn

19063

Suburban Research Associates, Media

19139

CRI Lifetree, Philadelphia

20170

NeuroScience, Inc, Herndon

27705

Duke Child and Family Study Center, Durham

30030

iResearch Atlanta, LLC, Decatur

30308

Atlanta Center for Medical Research, Atlanta

32216

Clinical Neuroscience Solutions Inc., Jacksonville

32751

Florida Research Center, Maitland

32771

Medical Research Group of Central Florida, Sanford

33143

Miami Research Associates, Miami

33334

Research Centers of America, LLC, Oakland Park

34201

Florida Clinical Research Center, LLC, Bradenton

38119

Clinical Neuroscience Solutions, Memphis

45408

Midwest Clinical Research Center, Dayton

46260

Goldpoint Clinical Research, Indianapolis

48307

Rochester Center for Behavioral Health, Rochester Hills

63301

Midwest Research Group, Saint Charles

73103

IPS Research Company, Oklahoma City

78731

Future Search Clinical Trials, LP, Austine

90720

Pharmacology Research Institute, Los Alamitos

91316

Pharmacology Research Institute, Encino

92056

Excell Research, Inc, Oceanside

92612

University of California at Irvine, Irvine

92645

Collaborative Neuroscience Network Inc, Garden Grove

92701

Neuropsychiatric Research Center of Orange County, Santa Ana

97210

Oregon Center for Clinical Investigations, Inc., Portland

98033

Eastside Therapeutic Resource, Kirkland

98104

Summit Research Network, LLC-Seattle, Seattle

92660-2452

Pharmacology Research Institute, Newport Beach

08002

Center for Emotional Fitness, Cherry Hill

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT01692782 - Adult Attention Deficit Hyperactivity Disorder | Biotech Hunter | Biotech Hunter